The prognostic value of LDH in patients with good risk metastatic seminoma treated with single-agent Carboplatin AUC 10

Abstract

Raised lactate dehydrogenase (LDH) is a surrogate marker for disease burden and an independent adverse prognostic factor for IGCCCG good risk metastatic seminoma patients treated with cisplatin and etoposide-based chemotherapy (Beyer et al, 2021. Patients with a LDH greater than 2.5 upper limit of normal (ULN) has 3-year progression free survival (PFS) of 80%. Therapy de-escalation using carboplatin AUC10 monotherapy has similar outcomes with fewer toxicities. However, the prognostic value of LDH and specific outcomes of patients with raised LDH in patients treated with carboplatin AUC10 has not been described.